Harry B Greenberg
Academic Appointments
- Professor, Medicine - Gastroenterology & Hepatology
- Member, Bio-X
- Member, Stanford Cancer Institute
- Member, Child Health Research Institute
- Professor, Microbiology & Immunology
Key Documents
Contact Information
- Academic Offices
Personal Information Email Tel (650) 725-9722Alternate Contact Zaida Esquivel Administrative Associate Email Tel Work (650) 725-9722
Professional Overview
Administrative Appointments
- Director of Spectrum: the Stanford Center for Clinical and Translational Science (CTSA), Stanford University (2008 - present)
- Senior Associate Dean for Research, Stanford University School of Medicine (2002 - present)
Honors and Awards
- member, ASCI (1980)
- Member, AAP (1992)
- Fellow, AAAS (2003)
- Senior Editor, J Virology (2003-)
Professional Education
| BA: | Dartmouth College, History (1966) |
| MD: | Columbia College of P&S, Medicine (1970) |
| Board Cerification: | Bellvue Hospital, Internal Medicine (1973) |
| Board Certification: | Stanford Medical School, Gastroenterology (1977) |
Graduate & Fellowship Program Affiliations
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
Dr. Greenberg's current interests are in pathogenic viruses that infect the GI tract, liver and respiratory tract. His primary focus is on molecular mechanisms of pathogenesis, viral determinants of protective immunity, the molecular basis of host range, virulence and tissue tropism, vaccine development, viral immunology, and epidemiology with specific emphasis on the role of enteric viruses in less developed countries. Some of the ongoing studies in the lab deal with the following questions:
(i)What rotavirus gene(s) code for host range restriction, virulence and immunity? These studies involve the use of genetic analysis and studies of humoral and cellular immunity.
(ii)What proteins and what regions of the rotavirus proteins code for neutralizing epitopes, cell fusion activity, viral receptors, protective immunity? These studies involve sequence analysis, site-specific mutagenesis, and expression of viral genes.
(iii)What host cell genes are regulated by rotavirus replication in vitro and in vivo. These studies focus on microarray analysis and cell biology.
(iv)What are the immune effector mechanisms that mediate protection from and resolution of rotavirus infection? These studies involve animal models, cell transfer studies, FACS analysis and transgenic mice.
(v)What are the mechanisms by which class I restricted CD8 T cells modulate HCV infection. These studies involve analysis of peripheral and liver infiltrating human T cells using intracellular cytokine and tetramer techniques.
(vi)What is the basis of interferon effects on HCV? This analysis focuses on in vitro and in vivo microarray studies.
(Vii)What are the determinants of immunity to influenza following live and inactivated virus vaccination?
Publications
- Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza virus A subtype H1N1 vaccine. J Infect Dis. 2013; (2): 288-96
- Lineage structure of the human antibody repertoire in response to influenza vaccination. Sci Transl Med. 2013; (171): 171ra19
- Cell-free production of trimeric influenza hemagglutinin head domain proteins as vaccine antigens. Biotechnol Bioeng. 2012; (12): 2962-9
- Innate immune response to homologous rotavirus infection in the small intestinal villous epithelium at single-cell resolution. Proc Natl Acad Sci U S A. 2012; (50): 20667-72
- Rhesus rotavirus trafficking during entry into MA104 cells is restricted to the early endosome compartment. J Virol. 2012; (7): 4009-13
- Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest. 2011; (8): 3109-19
Help
Trial Administration